Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Legend Biotech Corp ADR (NASDAQ: LEGN) was $23.88 for the day, down -8.58% from the previous closing price of $26.12. In other words, the price has decreased by -$8.58 from its previous closing price. On the day, 5.37 million shares were traded. LEGN stock price reached its highest trading level at $26.02 during the session, while it also had its lowest trading level at $23.87.
Ratios:
Our analysis of LEGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when GenScript Corporation bought 203,586 shares for $30.29 per share.
Casey Patrick John bought 1,000 shares of LEGN for $33,285 on Sep 26 ’25. On Sep 24 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,370 shares for $33.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 4410386944 and an Enterprise Value of 9808281600. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.85 while its Price-to-Book (P/B) ratio in mrq is 4.36. Its current Enterprise Value per Revenue stands at 10.79 whereas that against EBITDA is -54.118.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.11, which has changed by -0.27120537 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $24.11. The 50-Day Moving Average of the stock is -22.10%, while the 200-Day Moving Average is calculated to be -29.48%.
Shares Statistics:
LEGN traded an average of 1.63M shares per day over the past three months and 2705930 shares per day over the past ten days. A total of 184.69M shares are outstanding, with a floating share count of 180.91M. Insiders hold about 2.05% of the company’s shares, while institutions hold 44.43% stake in the company. Shares short for LEGN as of 1763078400 were 10945914 with a Short Ratio of 6.71, compared to 1760486400 on 11404545. Therefore, it implies a Short% of Shares Outstanding of 10945914 and a Short% of Float of 11.3299996.
Earnings Estimates
The dynamic stock of Legend Biotech Corp ADR (LEGN) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.79 and -$1.59 for the fiscal current year, implying an average EPS of -$1.04. EPS for the following year is $0.49, with 9.0 analysts recommending between $0.99 and $0.07.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 11 analysts. It ranges from a high estimate of $368.26M to a low estimate of $302.15M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 11 analysts are estimating revenue of $332.02M. There is a high estimate of $378.75M for the next quarter, whereas the lowest estimate is $301.83M.
A total of 14 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.01B, resulting in an average revenue estimate of $1.04B. In the same quarter a year ago, actual revenue was $627.24MBased on 14 analysts’ estimates, the company’s revenue will be $1.57B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.37B.
